Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Sebaceous glands are involved in various skin disorders, some treatable with medications like finasteride and minoxidil.

Some alopecia treatments might help treat COVID-19, but more research is needed.

Key genes linked to hair growth and cancer were identified in hairless mice.

Several new treatments for different types of hair loss show promise in improving patient quality of life.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

STAT3 signaling is important for healthy skin and hair follicles, and its disruption can lead to skin conditions like atopic dermatitis.

Using a combination of specific cell cycle regulators is better for safely keeping hair root cells alive indefinitely compared to cancer-related methods.

JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.

XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.

Chronic inflammatory skin diseases are caused by disrupted interactions between skin cells and immune cells.

Oxidative stress may contribute to hair loss in alopecia areata and antioxidants could potentially help as a treatment.

A new botanical treatment improved hair growth and symptoms in lichen planopilaris patients.

New treatments for vitiligo may focus on protecting melanocyte stem cells from stress and targeting specific pathways involved in the condition.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

The health of the gut may be important in developing new ways to prevent, diagnose, and treat alopecia areata.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.

SCD-153 shows promise as an effective topical treatment for alopecia areata.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Stem cells could improve hair growth and new treatments for baldness are being researched.

Dermatologists often neglect hair disorders due to complexity and lack of clear treatments, impacting patient care and highlighting the need for better education and interest in this area.

New treatments for hair loss show promise but need more research to confirm safety and effectiveness.

Alopecia Areata is an autoimmune condition causing hair loss, influenced by genetics, environment, and possibly improved by anti-MIF therapy, with many patients experiencing regrowth within a year.

NF-κB signaling is crucial in many diseases and can be targeted for new treatments.

Certain genetic variants linked to immune response increase the risk of alopecia areata in Taiwanese people.

Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.

The analysis aims to identify the most effective and safest treatments for alopecia areata.

A new mutation in the TMEM173 gene and a risk allele in IFIH1 cause a unique set of immune-related symptoms.